<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Ibio, Inc. — News on 6ix</title>
<link>https://6ix.com/company/ibio-inc</link>
<description>Latest news and press releases for Ibio, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 08 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/ibio-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d75cd051cc36e475338909.webp</url>
<title>Ibio, Inc.</title>
<link>https://6ix.com/company/ibio-inc</link>
</image>
<item>
<title>iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia</title>
<link>https://6ix.com/company/ibio-inc/news/ibio-received-regulatory-clearance-to-initiate-its-phase-1-clinical-trial-of-ibio-600-in-australia</link>
<guid isPermaLink="true">https://6ix.com/company/ibio-inc/news/ibio-received-regulatory-clearance-to-initiate-its-phase-1-clinical-trial-of-ibio-600-in-australia</guid>
<pubDate>Wed, 08 Apr 2026 04:00:00 GMT</pubDate>
<description>IBIO-600 is a potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body compositionFirst</description>
</item>
<item>
<title>iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)</title>
<link>https://6ix.com/company/ibio-inc/news/ibio-to-provide-an-update-on-cardiopulmonary-program-targeting-pulmonary-hypertension-associated-with-heart-failure-with-preserved-ejection-fraction-ph-hfpef</link>
<guid isPermaLink="true">https://6ix.com/company/ibio-inc/news/ibio-to-provide-an-update-on-cardiopulmonary-program-targeting-pulmonary-hypertension-associated-with-heart-failure-with-preserved-ejection-fraction-ph-hfpef</guid>
<pubDate>Mon, 16 Mar 2026 20:30:00 GMT</pubDate>
<description>Company to host corporate update call on Tuesday, March 17, at 4 p.m. ETSAN DIEGO, March 16, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases, today announced the Company will host a conference call on Tuesday, March 17, at 4 p.m. ET. The conference call will address iBio’s strategic pipeline expansion into pulmonary hypertension associated with heart failure with preserved ejection fraction (</description>
</item>
<item>
<title>iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss</title>
<link>https://6ix.com/company/ibio-inc/news/ibio-reports-preclinical-body-composition-data-from-obese-non-human-primates-treated-with-ibio-610-a-potential-first-in-class-treatment-for-fat-selective-weight-loss</link>
<guid isPermaLink="true">https://6ix.com/company/ibio-inc/news/ibio-reports-preclinical-body-composition-data-from-obese-non-human-primates-treated-with-ibio-610-a-potential-first-in-class-treatment-for-fat-selective-weight-loss</guid>
<pubDate>Mon, 09 Mar 2026 11:00:00 GMT</pubDate>
<description>Study demonstrated reduction of 6.7% visceral fat and 5.2% total fat mass in obese non-human primates (NHPs) despite high-calorie dietSAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases, today announced new preclinical data from its obese non-human primate (NHP) study evaluating IBIO-610, potentially a first-in-class Activin E antibody candidate. The preclinical body composi</description>
</item>
<item>
<title>iBio to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/ibio-inc/news/ibio-to-participate-in-upcoming-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/ibio-inc/news/ibio-to-participate-in-upcoming-investor-conferences</guid>
<pubDate>Tue, 24 Feb 2026 12:00:00 GMT</pubDate>
<description>SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), an AI-driven innovator of precision antibody therapies, today announced that Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer, and Felipe Duran, Chief Financial Officer, will participate in fireside chats at the Oppenheimer 36th Annual Healthcare Life Sciences Conference and the Leerink Global Healthcare Conference. Oppenheimer 36th Annual Healthcare Life Sciences ConferencePresentation Date:</description>
</item>
<item>
<title>iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/ibio-inc/news/ibio-reports-q2-fiscal-year-2026-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/ibio-inc/news/ibio-reports-q2-fiscal-year-2026-financial-results-and-provides-corporate-update</guid>
<pubDate>Tue, 10 Feb 2026 05:00:00 GMT</pubDate>
<description>Secured $26 Million in PIPE Financing Led by a Top-Tier Biotech Investor to Advance Preclinical Programs and Extend Cash Runway Progressed Pipeline with New</description>
</item>
<item>
<title>iBio Announces $26 Million Private Placement</title>
<link>https://6ix.com/company/ibio-inc/news/ibio-announces-dollar26-million-private-placement</link>
<guid isPermaLink="true">https://6ix.com/company/ibio-inc/news/ibio-announces-dollar26-million-private-placement</guid>
<pubDate>Fri, 09 Jan 2026 05:00:00 GMT</pubDate>
<description>SAN DIEGO, Jan. 09, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced that it has</description>
</item>
<item>
<title>iBio to Participate in the 8th Annual Evercore Healthcare Conference</title>
<link>https://6ix.com/company/ibio-inc/news/ibio-to-participate-in-the-8th-annual-evercore-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/ibio-inc/news/ibio-to-participate-in-the-8th-annual-evercore-healthcare-conference</guid>
<pubDate>Mon, 24 Nov 2025 21:15:00 GMT</pubDate>
<description>SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), an AI-driven innovator of precision antibody therapies, today announced that it will participate in the 8th Annual Evercore Healthcare Conference, taking place December 2–4, 2025, in Miami. Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer of iBio, will participate in a fireside chat on Thursday, December 4, 2025, at 8:45 a.m. ET. Dr. Brenner will outline iBio’s ongoing efforts to move its next</description>
</item>
<item>
<title>iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/ibio-inc/news/ibio-reports-q1-fiscal-year-2026-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/ibio-inc/news/ibio-reports-q1-fiscal-year-2026-financial-results-and-provides-corporate-update</guid>
<pubDate>Wed, 12 Nov 2025 05:00:00 GMT</pubDate>
<description>Strengthened cash position and extended runway into the fourth quarter of fiscal year 2027 after closing underwritten public offering with up to potentially</description>
</item>
<item>
<title>iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance</title>
<link>https://6ix.com/company/ibio-inc/news/ibio-unveils-new-non-human-primate-data-on-ibio-610-an-activin-e-antibody-with-strong-therapeutic-potential-for-fat-selective-weight-loss-and-weight-maintenance</link>
<guid isPermaLink="true">https://6ix.com/company/ibio-inc/news/ibio-unveils-new-non-human-primate-data-on-ibio-610-an-activin-e-antibody-with-strong-therapeutic-potential-for-fat-selective-weight-loss-and-weight-maintenance</guid>
<pubDate>Thu, 30 Oct 2025 11:00:00 GMT</pubDate>
<description>Previously reported data showed that in a diet-induced obesity mouse model, IBIO-610 drives fat-selective, GLP-1-synergistic weight loss and prevents weight regain following GLP-1 treatment discontinuation New non-human primate data projects a human half-life of up to 100 days, potentially enabling treatment with only twice-yearly dosing Extended half-life data and differentiated mechanism of action reinforce IBIO-610’s potential as a leading next-generation therapy for obesity and cardiometabol</description>
</item>
<item>
<title>iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference</title>
<link>https://6ix.com/company/ibio-inc/news/ibio-to-participate-in-the-guggenheim-2nd-annual-healthcare-innovation-conference</link>
<guid isPermaLink="true">https://6ix.com/company/ibio-inc/news/ibio-to-participate-in-the-guggenheim-2nd-annual-healthcare-innovation-conference</guid>
<pubDate>Thu, 23 Oct 2025 11:00:00 GMT</pubDate>
<description>SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), an AI-driven innovator of precision antibody therapies, today announced that it will participate in the Guggenheim 2nd Annual Healthcare Innovation Conference, taking place November 10–12, 2025 in Boston. Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer of iBio, will participate in a fireside chat on Monday, November 10, 2025, at 8:30 a.m. ET to discuss the Company’s continued development in b</description>
</item>
<item>
<title>iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025</title>
<link>https://6ix.com/company/ibio-inc/news/ibio-to-present-new-preclinical-data-on-its-activin-e-antibody-at-two-upcoming-scientific-conferences-obesityweekr-and-pegs-europe-2025</link>
<guid isPermaLink="true">https://6ix.com/company/ibio-inc/news/ibio-to-present-new-preclinical-data-on-its-activin-e-antibody-at-two-upcoming-scientific-conferences-obesityweekr-and-pegs-europe-2025</guid>
<pubDate>Tue, 21 Oct 2025 11:00:00 GMT</pubDate>
<description>SAN DIEGO, Oct. 21, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced that Cory Schwartz, Ph.D., Director of Research and Early Development at iBio, will deliver an oral presentation at ObesityWeek 2025 November 4-7 in Atlanta. In addition, Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer of iBio, will deliver an oral presentation at PEGS Europe 2025 November 11–13 in Lisbon. “We are excited</description>
</item>
<item>
<title>iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/ibio-inc/news/ibio-reports-fiscal-year-2025-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/ibio-inc/news/ibio-reports-fiscal-year-2025-financial-results-and-provides-corporate-update</guid>
<pubDate>Fri, 05 Sep 2025 04:00:00 GMT</pubDate>
<description>SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced its financial</description>
</item>
<item>
<title>iBio Announces Closing of $50 Million Public Offering</title>
<link>https://6ix.com/company/ibio-inc/news/ibio-announces-closing-of-dollar50-million-public-offering</link>
<guid isPermaLink="true">https://6ix.com/company/ibio-inc/news/ibio-announces-closing-of-dollar50-million-public-offering</guid>
<pubDate>Mon, 25 Aug 2025 04:00:00 GMT</pubDate>
<description>Total gross proceeds of $100 million if all Series G warrants and Series H warrants are exercised for cash Financing was led by Balyasny Asset Management and</description>
</item>
<item>
<title>iBio Announces Pricing of $50 Million Public Offering</title>
<link>https://6ix.com/company/ibio-inc/news/ibio-announces-pricing-of-dollar50-million-public-offering</link>
<guid isPermaLink="true">https://6ix.com/company/ibio-inc/news/ibio-announces-pricing-of-dollar50-million-public-offering</guid>
<pubDate>Tue, 19 Aug 2025 04:00:00 GMT</pubDate>
<description>SAN DIEGO, Aug. 19, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced the pricing of</description>
</item>
<item>
<title>iBio Announces Proposed Public Offering</title>
<link>https://6ix.com/company/ibio-inc/news/ibio-announces-proposed-public-offering</link>
<guid isPermaLink="true">https://6ix.com/company/ibio-inc/news/ibio-announces-proposed-public-offering</guid>
<pubDate>Mon, 18 Aug 2025 04:00:00 GMT</pubDate>
<description>SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced it has</description>
</item>
<item>
<title>iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results</title>
<link>https://6ix.com/company/ibio-inc/news/ibio-and-astralbio-unveil-obesity-program-with-novel-amylin-agonist-antibody-demonstrating-promising-in-vivo-results</link>
<guid isPermaLink="true">https://6ix.com/company/ibio-inc/news/ibio-and-astralbio-unveil-obesity-program-with-novel-amylin-agonist-antibody-demonstrating-promising-in-vivo-results</guid>
<pubDate>Tue, 24 Jun 2025 11:00:00 GMT</pubDate>
<description>Lead amylin receptor agonist engineered antibody significantly reduced acute food intake in a mouse model of obesity, comparable to the efficacy of a leading amylin peptide agonist Findings support the potential of antibody-based agonists to address the growing demand for safer, longer-acting treatments for obesity and cardiometabolic diseases Conference call today, June 24 at 8:30 a.m. ET to discuss new pre-clinical data and obesity pipeline SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- iBio, In</description>
</item>
<item>
<title>iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call</title>
<link>https://6ix.com/company/ibio-inc/news/ibio-presents-next-generation-obesity-and-cardiometabolic-pipeline-candidates-on-june-24-conference-call</link>
<guid isPermaLink="true">https://6ix.com/company/ibio-inc/news/ibio-presents-next-generation-obesity-and-cardiometabolic-pipeline-candidates-on-june-24-conference-call</guid>
<pubDate>Mon, 23 Jun 2025 20:15:00 GMT</pubDate>
<description>Review of promising Myostatin and Activin E antibody data iBio to announce 3rd target in Astral Bio Collaboration Conference call Tuesday, June 24 at 8:30 a.m. ET SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced the Company will host a conference call on Tuesday, June 24, at 8:30 a.m. ET to review its latest advances in obesity and cardiometabolic disease treatments and announce a third target in the A</description>
</item>
<item>
<title>iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment</title>
<link>https://6ix.com/company/ibio-inc/news/ibio-initiates-non-human-primate-study-of-first-in-class-activin-e-antibody-following-positive-preclinical-data-demonstrating-prevention-in-weight-regain-after-glp-1-treatment</link>
<guid isPermaLink="true">https://6ix.com/company/ibio-inc/news/ibio-initiates-non-human-primate-study-of-first-in-class-activin-e-antibody-following-positive-preclinical-data-demonstrating-prevention-in-weight-regain-after-glp-1-treatment</guid>
<pubDate>Mon, 16 Jun 2025 11:00:00 GMT</pubDate>
<description>iBio nominates IBIO-610 as development candidate for its first-in-class Activin E antibody New study aims to evaluate the half-life of IBIO-610 in obese, elderly non-human primates (NHP) and assess early signs of efficacy on fat reduction and body composition Mouse study shows IBIO-610 alone drives an overall body weight loss of 8.9%*, and prevents weight regain following GLP-1 treatment in obese mice, results of which will be presented at ADA on Monday June 23rd SAN DIEGO, June 16, 2025 (GLOBE</description>
</item>
<item>
<title>iBio’s First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model</title>
<link>https://6ix.com/company/ibio-inc/news/ibios-first-in-class-activin-e-antibody-achieves-greater26percent-fat-reduction-without-muscle-loss-and-shows-synergy-with-glp-1s-in-preclinical-model</link>
<guid isPermaLink="true">https://6ix.com/company/ibio-inc/news/ibios-first-in-class-activin-e-antibody-achieves-greater26percent-fat-reduction-without-muscle-loss-and-shows-synergy-with-glp-1s-in-preclinical-model</guid>
<pubDate>Mon, 05 May 2025 12:00:00 GMT</pubDate>
<description>Activin E antibody demonstrates significant decrease in fat in obese mice by reducing visceral fat depots, which are strongly linked to increased risk of cardiovascular and metabolic diseases, resulting in a 26% reduction in fat mass with no loss in muscleStrong synergistic effect on fat mass (77% reduction) was observed when the Activin E antibody was combined with a GLP-1 receptor agonist, resulting in total weight loss of 35.3%, 7.5% greater than GLP-1 alone SAN DIEGO, May 05, 2025 (GLOBE NEW</description>
</item>
<item>
<title>iBio Reports Fiscal Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/ibio-inc/news/ibio-reports-fiscal-third-quarter-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/ibio-inc/news/ibio-reports-fiscal-third-quarter-2025-financial-results</guid>
<pubDate>Fri, 02 May 2025 12:00:00 GMT</pubDate>
<description>SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq:IBIO), today reported financial results for the third quarter ended March 31, 2025, and provided a corporate update on its progress. “During the third quarter we were able to broaden our access to investors given our move to Nasdaq and subsequently in April, strengthened our financial position with a $6.2 million warrant-inducement equity raise, positioning us for continued growth and keeping us on track for regulatory submission of</description>
</item>
</channel>
</rss>